References
- DeSantis CE, Miller KD, Goding Sauer A, et al. Cancer statistics for African Americans, 2019. CA Cancer J Clin. 2019;69(3):211–233.
- Rajkumar SV, Kumar S. Multiple myeloma current treatment algorithms. Blood Cancer J. 2020;10(9):94.
- Ailawadhi S, Frank RD, Advani P, et al. Racial disparity in utilization of therapeutic modalities among multiple myeloma patients: a SEER-Medicare analysis. Cancer Med. 2017;6(12):2876–2885.
- Costa LJ, Huang JX, Hari PN. Disparities in utilization of autologous hematopoietic cell transplantation for treatment of multiple myeloma. Biol Blood Marrow Transplant. 2015;21(4):701–706.
- Samala RV, Valent J, Noche N, et al. Palliative care in patients with multiple myeloma. J Pain Symptom Manage. 2019;58(6):1113–1118.
- Al Hadidi S, Mims M, Miller-Chism CN, et al. Participation of African American persons in clinical trials supporting U.S. Food and Drug Administration approval of cancer drugs. Ann Intern Med. 2020;173(4):320–322.
- Al-Hamadani M, Hashmi SK, Go RS. Use of autologous hematopoietic cell transplantation as initial therapy in multiple myeloma and the impact of socio-geo-demographic factors in the era of novel agents. Am J Hematol. 2014;89(8):825–830.
- Bhatnagar V, Gormley N, Kazandjian D, et al. FDA analysis of racial demographics in multiple myeloma trials. Blood. 2017;130(Suppl. 1):4352.
- Ailawadhi S, Parikh K, Abouzaid S, et al. Racial disparities in treatment patterns and outcomes among patients with multiple myeloma: a SEER-Medicare analysis. Blood Adv. 2019;3(20):2986–2994.
- HCUP NIS Database Documentation. Healthcare cost and utilization project (HCUP); 2021. Rockville (MD): Agency for Healthcare Research and Quality. Available from: www.hcup-us.ahrq.gov/db/nation/nis/nisdbdocumentation.jsp
- Elixhauser A, Steiner C, Harris DR, et al. Comorbidity measures for use with administrative data. Med Care. 1998;36:8–27.
- National Cancer Institute. Joinpoint regression program, version 4.2.0.2, statistical methodology and applications branch, surveillance research program; 2021; [cited 2021 Mar 11]. Available from: http://surveillance.cancer.gov/joinpoint/
- Perrot A, Lauwers-Cances V, Cazaubiel T, et al. Early versus late autologous stem cell transplant in newly diagnosed multiple myeloma: long-term follow-up analysis of the IFM 2009 trial [abstract #143]. Blood (ASH Annual Meeting Abstracts); 2020. p. 136.
- Dingli D, Ailawadhi S, Bergsagel PL, et al. Therapy for relapsed multiple myeloma: guidelines from the Mayo stratification for myeloma and risk-adapted therapy. Mayo Clin Proc. 2017;92(4):578–598.
- Attal M, Lauwers-Cances V, Hulin C, et al. Lenalidomide, bortezomib, and dexamethasone with transplantation for myeloma. N Engl J Med. 2017;376(14):1311–1320.
- Auner HW, Pavlu J, Szydlo R, et al. Autologous haematopoietic stem cell transplantation in multiple myeloma patients from ethnic minority groups in an equal access healthcare system. Br J Haematol. 2012;157(1):125–127.
- Manojlovic Z, Christofferson A, Liang WS, et al. Comprehensive molecular profiling of 718 multiple myelomas reveals significant differences in mutation frequencies between African and European descent cases. PLoS Genet. 2017;13(11):e1007087.
- Ailawadhi S, Jacobus S, Sexton R, et al. Disease and outcome disparities in multiple myeloma: exploring the role of race/ethnicity in the cooperative group clinical trials. Blood Cancer J. 2018;8(7):67.
- Pulte ED, Nie L, Gormley N, et al. Survival of ethnic and racial minority patients with multiple myeloma treated with newer medications. Blood Adv. 2018;2(2):116–119.
- Fillmore NR, Yellapragada SV, Ifeorah C, et al. With equal access, African American patients have superior survival compared to white patients with multiple myeloma: a VA study. Blood. 2019;133(24):2615–2618.
- Porta-Sales J, Guerrero-Torrelles M, Moreno-Alonso D, et al. Is early palliative care feasible in patients with multiple myeloma? J Pain Symptom Manage. 2017;54(5):692–700.
- Baughn LB, Pearce K, Larson D, et al. Differences in genomic abnormalities among African individuals with monoclonal gammopathies using calculated ancestry. Blood Cancer J. 2018;8:96–106.
- Munjuluri A, Fillmore N, Cirstea D, et al. With equal access, African Americans with non-del17p multiple myeloma have superior overall survival, but del17p still carries poor prognosis across race: a VA study. Blood. 2019;134(Suppl. 1):4388.